Page 15 - Pharma Sector

Alarm bells over pill to cure pharma sector

The government plans to rationalise trade margins for many other medical devices, besides stents and knee implants

After GST jitters, pharma market back on growth track in August

Zydus Cadila had the highest growth rate of 15.7%, followed by Mankind Pharma's 11.1%

Hiring freeze in pharma sector as Centre pushes for generic medicine

Industry feels that doctors should be allowed to mention brand names, allowing the patient to choose

Will not sell BCPL, HAL to foreign companies: Govt

On the other hand, Minister says, closure of IDPL and RDPL will not affect domestic capacities

How pharma money reaches patient groups, even doctors on Twitter

The way we think about disease "is being subtly distorted" by financial ties

US pricing pressure to keep pharma companies' growth under check

However, the rupee depreciation against the dollar is expected to benefit export-oriented companies

Compass: Three companies that stand out in the Pharma space

Lupin, Glenmark and Natco seen gaining from strong domestic growth, clear FDA status and good pipeline of complex generics

Delhi High court quashes centre's ban on 344 combination drugs

The Kokate committee had observed that these Fixed Dose combinations did not have any therapeutic justification.

Pharma shares in focus; Lupin, Cipla, Dr Reddys up over 1%

Centre went about in a haphazard manner while banning the 344 FDCs, says High Court

Pharma firms divided on drug trial proposal

Some allege that the move to amend the validity period is being taken up at the behest of multinational drug cos

Domestic pharma firms zoom past MNCs in growth, market share

Domestic firms have deeper penetration, better brand recall, and strategic marketing practices that have enabled them to beat the MNC counterparts for years

Drug Price Control Order continues to drag growth of pharma industry

ICRA expects the DPCO segment of IPM to grow at 1-3 per cent for FY17 while the overall IPM will grow at 10-12 per cent

Pricing norms outdated, says NPPA chief

Bhupendra Singh also says DPCO also needs to be suitably tp help drug price controller fix the price of coronary stents

Drug firms worried over govt plan to add MRP to bar codes

An executive with a pharma firm pointed out that small towns might not have the requisite machinery to scan bar codes

Indian drug makers eye Japan for growth and to diversify risk

Japan is seeing a shift towards generics as its government tries to cut social welfare spending

Pharma sector grows 7.7% in May; FDC ban weighs

The Centre had recently banned 344 FDC drugs based on the findings of an expert panel

Pharma firms to step up R&D spending

Also, more focus on speciality drugs, in response to slowing US sales and pressures on pricing

Govt to develop 6 bulk drugs, medical devices parks

Once these parks become operational, they can bring down the cost of production of devices and bulk drugs by at least 30%

'We expect oncology segment to grow faster as we launch more products'

Q&A with Edgard Olaizola, MD, Eli Lilly India

Govt banned FDCs without considering clinical data: Pharma cos to Delhi HC

The companies termed as "absurd" the government's claim that it took the decision on the ground that safer alternatives were available